REIT│Singapore March 13, 2015 COMPANY NOTE First REIT FIRT SP / FRET.SI Market Cap Avg Daily Turnover Free Float US$726.2m US$0.76m 66.2% S$1,000m S$1.02m 727.3 m shares Current S$1.35 Target S$1.48 Prev. Target N/A Up/Downside 9.6% Conviction| All the right mix Notes from the Field ———————————————————————————————————————— TAN Xuan, CFA T (65) 6210 8698 E [email protected] PANG Ti Wee T (65) 6210 8609 E [email protected] LOCK Mun Yee T (65) 6210 8606 E [email protected] Company Visit Channel Check Expert Opinion Customer Views ———————————————————————————————————————— Show Style "View Doc Map" Indonesia healthcare expenditure is predicted to grow at CAGR of 14.9% between 2012-2018, and FIRT offers direct exposure to the growth of its healthcare infrastructure. FIRT’s key differentiating factor lies in its strong acquisition pipeline and inorganic growth, consisting of 9 completed assets and another 30 under development. We initiate coverage on FIRT with an Add rating and DDM-based target price of S$1.48 (discount rate 7.8%). FIRT’s FY15-16 dividend yield and P/BV of 6.5-6.6%/1.3x are higer than Parkway Life REIT’s 5.4-5.9%/1.4x and global healthcare REITs average of 5.5%/1.8x. Catalysts could come from potential yield-accretive acquisitions, plans to unlock value of untapped GFA and greater visibility on or completion of pipeline assets. Right market at right time Contents 1. BACKGROUND .............................................................. 5 2. RIGHT MARKET AT RIGHT TIME ................................. 7 3. RIGHT STRUCTURE ...................................................... 9 4. A STRONG PIPELINE .................................................. 12 5. VALUATION AND RECOMMENDATION ..................... 16 6. RISKS ........................................................................... 19 7. SWOT ANALYSIS ........................................................ 20 8. APPENDICES ............................................................... 21 Price Close 1.300 112.8 1.200 106.5 1.100 100.3 1.000 25 20 15 10 5 94.0 Vol m 119.0 Jun-14 Sep-14 Dec-14 Source: Bloomberg 52-week share price range 1.35 1.36 1.06 1.48 Current Target Indonesia healthcare needs are underserved and the government has ambitious healthcare plan that target to provide insurance coverage for all ~250m Indonesians by 2019 (up from the current 132m). As a result, Indonesia healthcare expenditure is predicted to grow at CAGR of 14.9% over 2012-2018, driven by a combination of rising affluence, changing lifestyles, urbanisation and pent-up demand. A key challenge that needs to be addressed is the lack of healthcare infrastructure, with Indonesia’s hospital-bed-topopulation and doctor-to-population ratios are only one-third and one-tenth that of global average. Right structure FIRT offers direct exposure to the growth of healthcare infrastructure in Indonesia, without foreign exchange and operating risks. Operating risks are limited, as Indonesian hospitals (95% of total assets) are master leased for 15+15 years, with the leases consisting of mainly base rental (annual escalation of 0-2%). Foreign exchange risk is mitigated by S$-denominated rental revenue from its Indonesian and Singapore assets. A strong pipeline Lippo Karawaci (LK), FIRT’s sponsor, and its subsidiary Siloam Hospitals plan to double bed capacity by 2017. As a result, FIRT has nine completed hospitals as potential acquisition targets and another 30 in the pipeline under development. We expect S$150m of acquisitions at 10% gross yield to increase DPU and target price by 4-6%, and lift gearing to 34.7% (with 50% debt funding). Thereafter, every S$50m acquisition will result in ~1% upside to our DPU assuming 25% debt funding. There is also hidden value within the portfolio in the form of untapped GFA. These have not been factored into our model. Financial Summary Relative to FSSTI (RHS) 1.400 Mar-14 | Gross Property Revenue (S$m) Net Property Income (S$m) Net Profit (S$m) Distributable Profit (S$m) Core EPS (S$) Core EPS Growth FD Core P/E (x) DPS (S$) Dividend Yield Asset Leverage BVPS (S$) P/BV (x) Recurring ROE % Change In DPS Estimates CIMB/consensus DPS (x) Dec-13A 83.3 80.2 117.8 52.09 0.083 33.1% 16.16 0.075 5.57% 31.9% 0.97 1.40 9.29% Dec-14A 93.3 91.9 90.6 58.22 0.073 (11.4%) 18.43 0.081 5.96% 32.7% 1.02 1.33 7.38% Dec-15F 101.5 100.0 59.0 65.80 0.080 9.8% 16.79 0.087 6.48% 32.9% 1.00 1.35 7.95% Dec-16F 103.4 101.9 60.5 67.29 0.082 1.8% 16.50 0.089 6.58% 33.0% 0.99 1.37 8.21% Dec-17F 105.4 103.9 62.0 68.81 0.083 1.8% 16.22 0.090 6.68% 33.1% 0.97 1.39 8.48% 1.04 1.02 1.01 SOURCE: CIMB, COMPANY REPORTS IMPORTANT DISCLOSURES, INCLUDING ANY REQUIRED RESEARCH CERTIFICATIONS, ARE PROVIDED AT THE END OF THIS REPORT. Designed by Eight, Powered by EFA First REIT│Singapore March 13, 2015 PEER COMPARISON Research Coverage Bloomberg Code FIRT SP PREIT SP RHT SP First REIT Parkway Life REIT Religare Health Trust Market SG SG SG Recommendation ADD ADD HOLD Rolling P/BV (x) Price 1.35 2.34 1.06 Target Price 1.48 2.60 1.06 Upside 9.6% 11.3% 0.2% Rolling Dividend Yield 1.800 12.0% 1.600 10.0% 1.400 1.200 8.0% 1.000 6.0% 0.800 0.600 4.0% 0.400 2.0% 0.200 0.000 Jan-11 Jan-12 Jan-13 First REIT Jan-14 0.0% Jan-11 Jan-15 Parkway Life REIT Religare Health Trust Peer Aggregate: P/BV vs Asset Leverage 1.40 35.0% 1.20 30.0% 1.00 25.0% 0.80 20.0% 0.60 15.0% 0.40 10.0% 0.20 5.0% Jan-14 Rolling P/BV (x) (lhs) Jan-14 Parkway Life REIT Jan-15 Religare Health Trust 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% Jan-13 Jan-13 Peer Aggregate: Dividend Yield 40.0% Jan-12 Jan-12 First REIT 1.60 0.00 Jan-11 Mkt Cap US$m 726 1,028 609 Jan-15 0.0% Jan-11 Jan-16 Jan-12 Asset Leverage (rhs) Jan-13 Jan-14 Jan-15 Rolling Dividend Yield Valuation First REIT Parkway Life REIT Religare Health Trust Dividend Yield Dec-14 Dec-15 5.96% 6.48% 4.92% 5.86% 7.33% 7.50% Dec-16 6.58% 5.38% 8.25% Dec-14 1.33 1.37 1.20 P/BV (x) Dec-15 1.35 1.38 1.23 DPS Growth Dec-14 Dec-15 7.0% 8.7% 7.1% 19.0% 9.9% 2.3% Dec-16 1.5% -8.1% 9.9% Asset Leverage Dec-14 Dec-15 32.7% 32.9% 35.0% 36.0% 10.7% 13.3% P/E (FD) (x) Dec-15 16.79 18.59 17.01 Dec-16 1.37 1.37 1.25 Dec-14 10.72 13.18 18.80 Dec-16 16.50 18.28 14.21 Dec-16 33.0% 36.0% 13.8% Fully Diluted EPS Growth Dec-14 Dec-15 Dec-16 -26.7% -36.2% 1.8% 9.3% -29.1% 1.7% 48.0% 10.5% 19.7% Growth and Returns First REIT Parkway Life REIT Religare Health Trust SOURCE: CIMB, COMPANY REPORTS Calculations are performed using EFA™ Monthly Interpolated Annualisation and Aggregation algorithms to December year ends. NPAT/EPS values for calculations and valuations are based on recurring and normalised values for GAAP and IFRS accounting standard companies respectively. 2 First REIT│Singapore March 13, 2015 BY THE NUMBERS Share price info Share px perf. (%) 1M 3M 12M Relative 2.0 4.0 16.1 Absolute 0.7 5.5 Major shareholders 25.0 % held LIPPO KARAWACI TBK PT 27.7 PT MENARA TIRTA INDAH 6.0 P/BV vs Asset Leverage Dividend Yield vs Net DPS - (S$) 1.80 1.60 1.40 1.20 1.00 0.80 0.60 0.40 0.20 0.00 Jan-11 Jan-12 Jan-13 Jan-14 Jan-15 Jan-16 Rolling P/BV (x) (lhs) 35.0% 31.1% 27.2% 23.3% 19.4% 15.6% 11.7% 7.8% 3.9% 0.0% 0.1000 0.0900 0.0800 0.0700 0.0600 0.0500 0.0400 0.0300 0.0200 0.0100 0.0000 Jan-11 Jan-12 Jan-13 Jan-14 Jan-15 Jan-16 Asset Leverage (rhs) DPS (lhs) 7.0% 6.3% 5.6% 4.9% 4.2% 3.5% 2.8% 2.1% 1.4% 0.7% 0.0% Dividend Yield (rhs) Profit & Loss Rental revenue in 2015 to grow from S$70m of acquisitions in 2014. Organically, growth should remain stable at ~2% p.a. (S$m) Rental Revenues Other Revenues Gross Property Revenue Total Property Expenses Net Property Income General And Admin. Expenses Management Fees Trustee's Fees Other Operating Expenses EBITDA Depreciation And Amortisation EBIT Net Interest Income Associates' Profit Other Income/(Expenses) Exceptional Items Pre-tax Profit Taxation Minority Interests Preferred Dividends Net Profit Distributable Profit Dec-13A 83.3 0.0 83.3 (3.1) 80.2 0.0 (8.0) (0.3) (1.7) 70.2 0.0 70.2 (12.2) Dec-14A 93.3 0.0 93.3 (1.4) 91.9 0.0 (9.1) (0.3) (1.9) 80.5 0.0 80.5 (15.0) Dec-15F 101.5 0.0 101.5 (1.5) 100.0 0.0 (9.1) (0.3) (2.0) 88.4 0.0 88.4 (15.0) Dec-16F 103.4 0.0 103.4 (1.5) 101.9 0.0 (9.1) (0.3) (2.1) 90.3 0.0 90.3 (15.1) Dec-17F 105.4 0.0 105.4 (1.6) 103.9 0.0 (9.1) (0.3) (2.1) 92.3 0.0 92.3 (15.1) 0.0 61.3 119.4 (1.5) 0.0 47.2 112.7 (22.1) 0.0 0.0 73.4 (14.4) 0.0 0.0 75.3 (14.8) 0.0 0.0 77.2 (15.1) 117.8 52.1 90.6 58.2 59.0 65.8 60.5 67.3 62.0 68.8 Cash Flow Acquisition size of an average ~S$100m for the past three years. We expect FIRT to continue growing through acquisitions given its strong asset pipeline. This is a key catalyst and has yet to be factored into our model. (S$m) Pre-tax Profit Depreciation And Non-cash Adj. Change In Working Capital Tax Paid Others Cashflow From Operations Capex Net Investments And Sale Of FA Other Investing Cashflow Cash Flow From Investing Debt Raised/(repaid) Equity Raised/(Repaid) Dividends Paid Cash Interest And Others Cash Flow From Financing Total Cash Generated Free Cashflow To Firm Free Cashflow To Equity Dec-13A 119.4 12.2 (0.3) (13.1) (54.8) 63.3 Dec-14A 112.7 15.0 8.9 (16.2) (39.7) 80.8 Dec-15F 73.4 15.0 (0.6) (14.4) 0.0 73.5 Dec-16F 75.3 15.1 (0.1) (14.8) 0.0 75.4 Dec-17F 77.2 15.1 (0.1) (15.1) 0.0 77.0 (142.0) 0.2 (141.8) 140.6 0.0 (42.8) (10.5) 87.3 8.8 (78.3) 49.9 (67.7) 0.2 (67.5) 39.3 0.0 (39.8) (13.8) (14.4) (1.1) 13.5 37.5 0.0 0.2 0.2 0.0 0.0 (64.5) (15.2) (79.7) (6.0) 73.9 58.7 0.0 0.2 0.2 0.0 0.0 (65.9) (15.2) (81.2) (5.6) 75.8 60.5 0.0 0.1 0.1 0.0 0.0 (67.4) (15.2) (82.6) (5.5) 77.2 62.0 SOURCE: CIMB RESEARCH, COMPANY 3 First REIT│Singapore March 13, 2015 BY THE NUMBERS Balance Sheet Investment properties to remain stable, with limited impact from foreign exchange movements. We have yet to factor any revaluation gain into our model. (S$m) Total Investments Intangible Assets Other Long-term Assets Total Non-current Assets Total Cash And Equivalents Inventories Trade Debtors Other Current Assets Total Current Assets Trade Creditors Short-term Debt Other Current Liabilities Total Current Liabilities Long-term Borrowings Other Long-term Liabilities Total Non-current Liabilities Shareholders' Equity Minority Interests Preferred Shareholders Funds Total Equity Dec-13A 1,052 0 0 1,053 29 Dec-14A 1,172 0 1 1,173 28 Dec-15F 1,172 0 1 1,173 22 Dec-16F 1,172 0 1 1,173 17 Dec-17F 1,172 0 1 1,173 11 25 2 56 30 0 20 50 354 22 376 683 9 3 40 20 26 21 68 370 29 399 745 10 3 35 21 26 21 68 370 29 399 740 10 3 29 21 26 21 69 370 29 399 734 10 3 24 21 26 21 69 370 29 399 729 683 745 740 734 729 Dec-13A 44.5% 40.1% 96.3% 3.58% 5.68 1.3% 44% 1.12 1.12 0.59 12.2% Dec-14A 12.0% 14.5% 98.5% 7.05% 5.29 19.6% 64% 0.58 0.58 0.41 7.8% Dec-15F 8.8% 8.8% 98.5% 8.66% 5.81 19.6% 109% 0.50 0.50 0.32 4.9% Dec-16F 1.9% 1.9% 98.5% 1.50% 5.94 19.6% 109% 0.43 0.43 0.24 5.0% Dec-17F 1.9% 1.9% 98.5% 1.51% 6.06 19.6% 109% 0.35 0.35 0.16 5.2% Dec-13A N/A N/A N/A N/A 100.0% 1,052.3 N/A Dec-14A N/A N/A N/A N/A 100.0% 1,172.0 N/A Dec-15F N/A N/A N/A N/A 100.0% 1,172.0 N/A Dec-16F N/A N/A N/A N/A 100.0% 1,172.0 N/A Dec-17F N/A N/A N/A N/A 100.0% 1,172.0 N/A Key Ratios Growth from acquisitions. Gross Property Revenue Growth NPI Growth Net Property Income Margin DPS Growth Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Current Ratio Quick Ratio Cash Ratio Return On Average Assets Key Drivers High occupancy from master leases. Rental Rate Psf Pm (S$) Acq. (less development) (US$m) RevPAR (S$) Net Lettable Area (NLA) ('000 Sf) Occupancy (%) Assets Under Management (m) (S$) Funds Under Management (m) (S$) SOURCE: CIMB RESEARCH, COMPANY 4 First REIT│Singapore March 13, 2015 All the right mix 1. BACKGROUND Listed since Dec 2006, First Real Estate Investment Trust (FIRT) is a healthcare real estate investment trust (REIT) focusing on real estate assets in Asia that are primarily used for healthcare and healthcare-related purposes. FIRT’s S$1.17bn portfolio consists of 16 assets, of which 12 are located in Indonesia, three in Singapore and one in South Korea. Indonesian hospitals make up the bulk of its portfolio, at ~96% of the total value. PT Lippo Karawaci Tbk (LK) is the sponsor of FIRT and Bowsprit Capital, an indirect subsidiary of the sponsor, is the manager of FIRT. Figure 1: Overview of initial portfolio Usage MRCCC Siloam Hospitals Lippo Village Hospital Hospital Oncology Digestive Unit Neuroscience, Cardiology Siloam Hospitals Bali Siloam Hospitals TB Simatupang Hospital Trauma, Cardiology, Oncology, Neuroscience 2,489 18,605 4,145 17,442 Hospital Trauma, Orthopaedics, Cardiology 9,025 37,933 27,284 20,958 Purchase Price (S$m) 170.5 94.3 97.3 93.1 Appraised Value (S$m) 253.2 162.1 121.6 116.5 Centre of Excellence Land area (sq m) GFA (sq m) Max no. of Beds / Saleable rooms 375 260 295 271 Year of Building Completion 2010 1995 2012 2013 Lease Commencement Date 30-Dec-10 11-Dec-06 13-May-13 22-May-13 15 + 15 15 + 15 15 + 15 15 + 15 29-Dec-25 10-Dec-21 12-May-28 21-May-28 Lease Terms Lease Expiry Date SOURCES: CIMB, COMPANY REPORT Figure 2: Overview of initial portfolio (cont’d) Siloam Hospitals Manado & Hotel Aryaduta Manado Siloam Hospitals Kebon Jeruk Siloam Hospitals Makassar Integrated Hospital & Hotel Hospital Hospital Trauma Urology centre, Orthopaedics Trauma Cardiology 5,518 11,420 3,963 Hospital Urology, Internal Medicine, Trauma 9,900 36,051 18,316 14,307 11,125 Purchase Price (S$m) 83.6 50.6 59.3 35.0 Appraised Value (S$m) 104.2 91.9 72.3 46.0 224 beds / 200 rooms 201 416 126 Usage Centre of Excellence Land area (sq m) GFA (sq m) Max no. of Beds / Saleable rooms Siloam Hospitals Lippo Cikarang Year of Building Completion 2011 1991 2012 2002 Lease Commencement Date 30-Nov-12 11-Dec-06 30-Nov-12 31-Dec-10 Lease Terms Lease Expiry Date 15 + 15 15 + 15 15 + 15 15 + 15 29-Nov-27 10-Dec-21 29-Nov-27 30-Dec-25 SOURCES: CIMB, COMPANY REPORT 5 First REIT│Singapore March 13, 2015 Figure 3: Overview of initial portfolio (cont’d) Usage Siloam Sriwijaya Imperial Aryaduta Hotel & Country Club Hospital Hotel & Country Club Emergency, Trauma -- Siloam Hospitals Purwakarta Siloam Hospitals Surabaya Hospital Fertility services, Stroke centre -- 54,410 Hospital Emergency, Trauma, Health Ministry's BPJS Program 7,990 15,709 17,427 8,254 9,227 Purchase Price (S$m) 39.2 21.2 31.0 16.8 Appraised Value (S$m) 43.8 42.1 38.1 33.2 Centre of Excellence Land area (sq m) GFA (sq m) 6,862 Max no. of Beds / Saleable rooms 347 197 203 160 Year of Building Completion 2010 1994 2005 & 2008 1977 Lease Commencement Date 29-Dec-14 11-Dec-06 28-May-14 11-Dec-06 15 + 15 15 + 15 15 + 15 15 + 15 28-Dec-29 10-Dec-21 27-May-29 10-Dec-21 Lease Terms Lease Expiry Date SOURCES: CIMB, COMPANY REPORT Figure 4: Overview of initial portfolio (cont’d) The Lentor Residence Pacific Healthcare Nursing Home II @ Bukit Panjang Pacific Healthcare Nursing Home @ Bukit Panjang Sarang Hospital Nursing Home Nursing Home Nursing Home Hospital Land area (sq m) 2486 2,000 1,984 2,142 GFA (sq m) 4,005 3,563 3,593 4,982 13 11.5 11.8 US$13m 17.6 10.6 10.5 US$6.3m 208 265 259 217 2006 2004 2010 Usage Centre of Excellence Purchase Price (S$m) Appraised Value (S$m) Max no. of Beds / Saleable rooms Year of Building Completion Lease Commencement Date 1999 & 2013 (new extension building) 8-Jun-07 Lease Terms 10 + 10 Lease Expiry Date 7-Jun-17 11-Apr-07 11-Apr-07 10 + 10 (tenant has exercise the 10 + 10 (tenant has exercise the option) option) 10-Apr-27 10-Apr-27 5-Aug-11 10 + 10 4-Aug-21 SOURCES: CIMB, COMPANY REPORT 6 First REIT│Singapore March 13, 2015 2. RIGHT MARKET AT RIGHT TIME Right market Indonesia’s healthcare expenditure lags behind peers Indonesia’s healthcare expenditure lags those of regional peers, both in terms of per capita and as a percentage of GDP. Its healthcare expenditure per capita of US$61 in 2012 was a fraction those of developed countries’, about half of Malaysia’s and a quarter of Thailand’s. As a percentage of GDP, the healthcare expenditure of Indonesia only formed 3% in 2012, the lowest among its regional peers. Figure 5: Total healthcare expenditure as % GDP (2012) Figure 6: Healthcare expenditure per capita (2012) US$ 20.0% 18.0% 9,000 17.9% 8,000 16.0% Please fill in the values above to have them entered in your report 7,000 14.0% 6,000 12.0% 10.0% 8.0% 6.0% Title: Source: 8,895 5,000 9.4% 7.3% 4,000 6.6% 5.4% 4.7% 3,647 3,000 4.4% 4.0% 4.0% 4.0% 2,426 2,000 3% 2.0% 1,000 0.0% 0 SOURCES: CIMB, GLOBAL HEALTH EXPENDITURE DATABASE 419 322 115 108 102 69 61 SOURCES: CIMB, GLOBAL HEALTH EXPENDITURE DATABASE Healthcare expenditure to double from 2012 to 2018 According to Frost & Sullivan, Indonesia’s healthcare expenditure will expand by CAGR of 14.9% in 2012-2018. This would be driven by rising affluence, changing lifestyles, increasing urbanisation and pent-up demand. Right time Ambitious healthcare plans The Indonesian government has an ambitious healthcare insurance plan called the Jaminan Kesehatan Nasional (JKN). The plan, which was implemented on 1 Jan 2014, aims to unify various public insurance schemes under a single agency (BPJS Kesehatan) and provide better health insurance coverage for all Indonesians (~250m) by 2019. This is almost double of the current coverage of ~132m Indonesians. Healthcare infrastructure implementation is the main impediment to Since its implementation, the JKN has met with criticism on issues such as longer waiting times and poorer quality of care at participating hospitals. We think that this was due to healthcare infrastructure being spread too thin, a key issue that needs to be addressed in order to meet JKN’s 2019 target. Indonesia lacks both healthcare infrastructure and personnel. Despite the number of hospitals and hospital beds increasing by 12-15% p.a. in 2007- 2012, Indonesia’s 0.97 bed-per-1,000 population ratio is still well below the global average of 3.0 and the Organisation for Economic Co-operation and Development (OECD) average of 4.0 beds per 1,000 people. In addition, Indonesia has the one of the lowest number of doctors per 1,000 people in the region despite the country’s rising affluence levels. 7 First REIT│Singapore March 13, 2015 Figure 7: Hospital bed-to-population ratio Figure 8: Doctor-to-population ratio Doctors / 1,000 population 3.00 2.79 Beds / 1,000 population 3.50 3.00 2.95 2.84 Global avg = 3 2.84 Title: Source: Please fill in the values above to have them entered in your report 2.50 2.31 2.50 2.16 2.00 2.01 1.77 2.00 1.63 1.48 1.50 Global avg = 3 1.26 1.50 1.02 1.00 1.00 0.97 0.74 0.50 0.50 0.00 0.31 0.30 0.00 China US UK Singapore Thailand Malaysia India Indonesia UK SOURCES: CIMB, COMPANY REPORTS, WHO, OECD, MINISTRIES OF HEALTH US Singapore China Malaysia India Indonesia Thailand SOURCES: CIMB, COMPANY REPORTS, WHO, OECD, MINISTRIES OF HEALTH In an interview with the Jakarta Post, Fachmi Idris (BPJS Kesehatan’s president director) estimates that there will be enough doctors to serve all Indonesians by 2019, given the 6,000-10,000 graduates annually. As such, the government only needs to work on the supply of medical facilities, which is the responsibility of both the Health Ministry and local governments. We believe there is ample room for private healthcare providers to grow and fill the gap. 8 First REIT│Singapore March 13, 2015 3. RIGHT STRUCTURE FIRT is an optimal vehicle to ride on the growth of healthcare infrastructure in Indonesia without exposure to foreign exchange and operating risks. Strong sponsor and operator PT Lippo Karawaci Tbk (LK), FIRT’s sponsor, is Indonesia’s largest listed property company by assets (Rp35.7bn) and market cap (Rp25.5bn). LK operates four business divisions – namely residential and urban development, hospitals, commercial and asset management. It is also the fastest-growing Indonesian real estate group, with its market cap expanding by more than 10x since 2004. Siloam, LK’s listed subsidiary, is the market leader within the highly-fragmented private healthcare sector, with 7.4% market share in Indonesia. Its nearest competitor, Mitra, has only 3% market share and around one-third of its bed capacity. We believe that, together, Siloam and LK are well positioned to ride on the growth of the Indonesian healthcare sector. Figure 9: Private hospital market share, 2012 Siloam, 7.4% Mitra, 3.0% Figure 10: Hospital bed capacity, 2012 Awal Bros, 2.5% Sari Asih, 2.2% Title: Source: 3500 3000 3000 Please fill in the values above to have them entered in your report Hermina, 2.0% 2500 Ramsay, 1.6% 2000 Omni, 1.1% Mayapada, 0.5% 1500 1200 1000 1000 900 820 650 480 500 450 440 400 200 129 0 Others, 79.8% SOURCES: CIMB, FROST & SULLIVAN SOURCES: CIMB, FROST & SULLIVAN Limited operating risks There is limited operating risks, as Indonesian hospitals (95% of FIRT’s assets and FY14 revenue) are mostly master leased to LK for 15-year terms, with options to renew for another 15 years. The majority of its FY14 revenue consisted of base rental (97%), with annual escalation of a minimum 0% and maximum 2% and pegged to two times the growth of Singapore CPI. 9 First REIT│Singapore March 13, 2015 Figure 11: Lease structures Geography Base Rental Figure 12: Revenue breakdown by geography Variable Rental Singapore, 3% FX Indonesia Fixed base rental Annual escalation (2x % increase of Singapore CPI, min 0% and capped at 2%) 0.75-2.0% of Indonesia assets gross revenue SGD Singapore Fixed base rental Annual increment of 2% NA SGD Korea Fixed base rental Annual increment of 2% NA USD South Korea, 2% Indonesia, 95% SOURCES: CIMB, COMPANY REPORTS SOURCES: CIMB, COMPANY REPORTS Minimal foreign exchange risk Foreign exchange risk is mitigated by the rents of the Indonesian and Singaporean assets (98%) that are pegged to a fixed exchange rate throughout the lease term. One might argue that FIRT’s rental growth cap of 2% p.a. lags the double-digit growth of Indonesia’s healthcare expenditure. However, Figure 13 shows that FIRT’s base rental growth in Rupiah terms is comparable to that of Indonesia’s healthcare expenditure during times of Rupiah depreciation. As such, we believe that FIRT’s low rental growth cap is mitigated by the lower foreign exchange risk. Figure 13: Growth of FIRT’s base rent is comparable to that of Indonesia’s healthcare expenditure during times of Rupiah depreciation 30% 25% 20% 15% 10% 5% 0% 2008 2009 2010 2011 2012 2013 2014 -5% -10% -15% Appreciation / (depreciation) of Rp against S$ Growth in Indonesia healthcare expenditure in Rp terms Growth in FIRT base rent in Rp terms (on a same hospital basis) SOURCES: CIMB, COMPANY REPORTS Limited interest rate and refinancing risks Most of FIRT’s debt is denominated in S$ and spread out, with the earliest refinancing expected in 2017. Additionally, FIRT has hedged 95% of its debt against rising financing costs by funding 54% of its debt through fixed rate loans/bonds and 46% via partially-hedged term loans. As such, any changes in interest rates are likely to have limited impact on FY15-16 DPUs. 10 First REIT│Singapore March 13, 2015 Figure 14: Debt maturity profile Figure 15: Debt profile S$m Title: Source: 200 180 38.7% 160 Please fill in the values above to have them entered in your rep 35.1% 140 120 26.2% 100 100 91.6 Term loan (hedged), 46% 26.5 80 Fixed rate loan/bond, 54% 60 40 78.5 20 49.2 55.5 2017 2018 0 2015 2016 2019 SOURCES: CIMB, COMPANY REPORTS 11 SOURCES: CIMB, COMPANY REPORTS First REIT│Singapore March 13, 2015 4. A STRONG PIPELINE Nine completed potential assets for acquisition LK has given FIRT the right of first refusal (ROFR) to all its healthcare properties and currently operates 20 hospitals with a 4,758-bed capacity under its subsidiary, Siloam Hospitals. FIRT owns 11 of those assets and has the remaining nine completed hospitals as potential acquisition targets. Figure 16: Potential acquisition targets Location Bed capacity Centre of excellence Status SILOAM HOSPITALS JAMBI SILOAM HOSPITALS BALIKPAPAN SILOAM GENERAL HOSPITAL (RSUS) East Sumatera East Kalimantan Tangerang (West of Jakarta) 100 228 640 Emergency & trauma Emergency & trauma and Orthopedics - Mature Mature Opened in 2012 SOURCES: CIMB, COMPANY REPORT Figure 17: Potential acquisition targets (cont'd) Location Bed capacity Centre of excellence Status SILOAM HOSPITALS CINERE BIMC KUTA BIMC NUSA DUA Depok (South of Jakarta) Bali Bali 40 18 20 Cardiology Emergency & trauma Emergency & Cosmetic Surgery Opened in 2012 Opened in 2013 Opened in 2013 SOURCES: CIMB, COMPANY REPORT 12 First REIT│Singapore March 13, 2015 Figure 18: Potential acquisition targets (cont'd) Location Bed capacity Centre of excellence Status SILOAM HOSPITAL ASRI SILOAM HOSPITALS MEDAN SILOAM HOSPITALS KUPANG South Jakarta North Sumatera East Nusa Tenggara 40 388 405 Urology Opened in 2014 Opened in 4Q 2014 Opened in 4Q 2014 SOURCES: CIMB, COMPANY REPORT Another 30 in the pipeline We think the Indonesian private healthcare sector is in a sweet spot. On a whole, we believe rising income, urbanisation and the JKN will propel growth in the healthcare industry. However, we think the private sector will benefit more as more Indonesians could turn to private hospitals for better service given their frustration with the mandatory switch to JKN. In view of the strong anticipated growth in healthcare expenditure and current lack of infrastructure, Siloam has plans to expand its bed capacity to 10,000 beds and its network to 50 hospitals by 2017. It currently has 30 hospitals in various stages of development and expects its hospitals to grow to up to US$3.5bn in five years’ time. This gives FIRT an additional pipeline of 30 hospitals for acquisition upon asset completion. Figure 19: Number of Siloam Hospitals 50 50 45 40 35 CAGR = 43% 30 25 20 20 16 15 12 10 5 7 4 0 2010 2011 2012 2013 2014F 2017F SOURCES: CIMB, COMPANY REPORTS 13 First REIT│Singapore March 13, 2015 Scenario analysis We estimate S$150m in acquisitions will increase DPU and our target price by 4-6% and result in gearing of 34.7%, assuming 50% debt funding. To maintain a gearing of below 35%, we believe further acquisition will require a higher proportion of equity funding by above the S$150m mark, assuming the properties are not revalued. Assuming 25% debt funding, every S$50m of acquisition will result in ~1% increase in FY16 DPU. Figure 20: Scenario analysis on acquisition Impact to FY16 DPU Acquisition Size debt : equity funding ratio 75:25 50:50 25:75 S$50m S$100m S$150m S$200m 2.7% 2.0% 1.3% 5.2% 3.8% 2.5% 7.8% 5.6% 3.6% 10.2% 7.3% 4.6% Impact to target price Acquisition Size debt : equity funding ratio 75:25 50:50 25:75 S$50m S$100m S$150m S$200m 2.1% 1.4% 0.8% 4.2% 2.8% 1.5% 6.2% 4.1% 2.1% 8.2% 5.4% 2.8% Gearing Acquisition Size debt : equity funding ratio 75:25 50:50 25:75 S$50m S$100m S$150m S$200m 34.5% 33.5% 32.5% 36.0% 34.1% 32.2% 37.4% 34.7% 32.0% 38.7% 35.2% 31.7% SOURCES: CIMB, COMPANY REPORTS Our scenario analysis assumptions are: We assume a gross yield of 10% and net property income (NPI) margin of 98%. Historical acquisitions of Siloam-operated hospitals in 2010 and 2012-2014 were transacted at gross yields of 9.9-10.8%, although third-party acquisitions in Singapore (2007) and Korea (2011) were transacted at lower yields. We assume that the acquisition will make 50% rental contribution in FY15 and 100% from FY16 onwards. We do not factor any revaluation gains into our calculation of net gearing. We assume that equity is raised at the price of S$1.35/share. Figure 21: Historical acquisitions S$m 250 12.0% 10.8% 9.9% 9.9% 10.5% 10.0% 200 206 7.8% 190 8.0% 150 4.9% 143 6.0% 100 4.0% 70 50 2.0% 51 16 0 0.0% 2007 2010 2011 Acquisition size (LHS) 2012 2013 2014 Yield (RHS) SOURCES: CIMB, COMPANY REPORTS 14 First REIT│Singapore March 13, 2015 Hidden value There is hidden value in several properties within the portfolio, namely Siloam Hospitals Surabaya, Siloam Hospitals Kebon Jeruk and Imperial Aryaduta Hotel & Country Club. As shown in Figures 22-24, the existing properties, especially Imperial Aryaduta Hotel & Country Club, make up only a fraction of the land area and redevelopment could more than double the GFA of the properties. We understand that LK owns adjacent land surrounding Siloam Hospitals Surabaya and Siloam Hospitals Kebon Jeruk and plans to build an integrated development. We believe that FIRT could realise the land’s value without disrupting rental income by: 1) allowing LK to building a hospital adjacent to the existing asset, 2) doing an asset swap with LK upon completion, and 3) FIRT to top-up the excess value of the new property over the existing property. Assuming a value of S$425psf GFA (the average book value of FIRT’s existing Indonesian assets), the doubling of GFA at Siloam Hospitals Surabaya and Siloam Hospitals Kebon Jeruk would be identical to acquisitions of S$41m and S$83m, from FIRT’s perspective. Using assumptions similar to our sensitivity analysis on acquisitions, this could result in total 3-4% accretion to our FY15 DPU and target price, assuming 50% funding via debt. Figure 22: Siloam Hospitals Surabaya Figure 23: Siloam Hospitals Kebon Jeruk (West Jakarta) SOURCES: CIMB, COMPANY REPORTS SOURCES: CIMB, COMPANY REPORTS Figure 24: Imperial Aryaduta Hotel & Country Club SOURCES: CIMB, COMPANY REPORTS 15 First REIT│Singapore March 13, 2015 5. VALUATION AND RECOMMENDATION Initiate with Add and target price of S$1.48 We initiate coverage on FIRT with an Add rating and target price of S$1.45. This implies 1.48x FY15 P/BV, NPI yield of 6.6% and distribution yield of 5.9%. We use the dividend discount model (DDM) to value FIRT, the same valuation method that we used for all the REITs under our coverage. We assume cost of equity of 7.8%, derived using a risk-free rate of 3.0%, equity risk premium of 6.0% and beta of 0.8x. Our long-term growth rate is 2%, consistent with the growth cap placed on its Indonesian assets’ fixed rentals. Figure 25: Target price based on DDM sensitivity analysis and implied P/BV and FY15 NPI yields 7.4% 7.6% 1.49 1.54 1.59 1.65 1.71 1.44 1.48 1.53 1.59 1.65 Implied P/BV (x) 1.48 1.53 1.58 1.64 1.71 1.43 1.48 1.53 1.58 1.64 Implied FY14 NPI Yield 6.6% 6.4% 6.2% 6.1% 5.9% 6.7% 6.6% 6.4% 6.3% 6.1% Implied FY14 distribution yield 5.9% 5.7% 5.5% 5.3% 5.1% 6.1% 5.9% 5.7% 5.5% 5.3% Terminal Growth 1.50% 1.75% 2.00% 2.25% 2.50% Discount Rate 7.8% Target price (S$) 1.39 1.43 1.48 1.53 1.59 Implied P/BV range (x) 1.39 1.43 1.48 1.53 1.58 Implied FY15 NPI yield range (%) 6.9% 6.7% 6.6% 6.4% 6.3% Implied FY15 distribution yield (%) 6.3% 6.1% 5.9% 5.7% 5.5% 8.0% 8.2% 1.35 1.39 1.43 1.48 1.53 1.31 1.35 1.38 1.43 1.48 1.34 1.38 1.43 1.47 1.52 1.30 1.34 1.38 1.42 1.47 7.0% 6.9% 6.7% 6.6% 6.4% 7.2% 7.0% 6.9% 6.7% 6.6% 6.5% 6.3% 6.1% 5.9% 5.7% 6.7% 6.5% 6.3% 6.1% 5.9% SOURCES: CIMB, BLOOMBERG, COMPANY REPORTS Peer comparison There are currently three healthcare REITs/trusts listed in Singapore and FIRT is second in terms of asset size and market capitalisation. Figure 26: Overview of Healthcare S-REITs/BTs Asset base (S$m ) Market cap (S$m ) Sponsor No. of assets Bed capacity GFA (m sf) Capital m anagem ent Reported leverage Debt headroom (at 45% asset leverage) (S$m ) Debt m aturity profile (S$m ) 2015 expiry 2016 expiry 2017 expiry 2018 expiry 2019 expiry & beyond All-in financing cost Percentage of debt fixed First REIT 1,172 996 Religare Health Trust 857 842 Parkw ay Life REIT 1,537 1,422 PT Lippo Karaw aci Tdk Fortis Healthcare Limited Parkw ay Holdings Limited 16 4,024 2.7 14 3,594 3.6 41 721 2.7 33% 15% 35% 262 478 299 65 19 80 80 103 305 1.4% ~80% 141 156 105 ~4.5% 54% 63 ~4.5% 0% SOURCES: CIMB, COMPANY REPORTS 16 First REIT│Singapore March 13, 2015 Geography and asset class exposure: FIRT offers exposure to Indonesia, Religare Health Trust (RHT) to India and Parkway Life REIT (PREIT) to Singapore/Japan. Most of the healthcare assets are hospitals. Stability and growth: We believe PREIT and FIRT are similar and are more stable than their peers, as most of their revenues come from fixed rentals denominated in S$ or hedged in the long term. However, they have limited organic growth, as the REITs are more reliant on inorganic growth. RHT is probably more volatile, as it is subject to Rs:S$ fluctuations, but it offers higher organic growth given its greater proportion of variable fees. Figure 27: Geography split by asset value Figure 28: Assets split by asset value Figure 29: Estimated revenue split 100% 100% 90% 90% 100.0% Title: Source: 90.0% 80% 80% 70% 70% 70.0% 60% 60% 60.0% 50% 50% 50.0% 40% 40% 40.0% 30% 30% 30.0% 20% 20% 20.0% 10% 10% 10.0% 80.0% Please fill in the values above to have them entered in your Please re 0.0% 0% 0% FIRT Singapore RHT Indonesia Japan PREIT India Others SOURCES: CIMB, COMPANY REPORTS Title: Source FIRT RHT Hospitals PREIT PREIT FIRT Fixed Nursing homes SOURCES: CIMB, COMPANY REPORTS RHT Variable SOURCES: CIMB, COMPANY REPORTS Fee structure: The three healthcare peers have fairly similar fee structures, with a base fee of 0.3-0.4% p.a. of asset value and performance fee of 4.5-5.0% of NPI or distributable income. FIRT and PREIT have acquisition and divestment fees while RHT does not. Figure 30: Fee comparison First REIT Religare Health Trust Parkway Life REIT Structure REIT Business Trust REIT Base Fee 0.4% p.a. of the asset value 0.4% p.a. of the asset value 0.3% p.a. of the asset value 4.5% p.a. of Distributable Income 4.5% p.a. of NPI Performance Fee 5% p.a. of NPI Acquisition Fee 1% of the acquisition price - 1% of the acquisition price Divestment Fee 0.5% of the sale price - 0.5% of the sale price SOURCES: CIMB, COMPANY REPORTS Valuation: FIRT’s FY15 dividend yield of (6.5%) and P/BV (1.3x) is more favourable than those of its direct peer PREIT (5.9% and 1.4x). While healthcare REITs generally trade at higher P/BV multiples than S-REITs, FIRT’s FY15 dividend yield is on par with the S-REIT average of 6.7%. Additionally, FIRT’s FY15 dividend yield and P/BV appear attractive compared to the average of 5.5% and 1.76x of its global healthcare REIT peers. 17 First REIT│Singapore March 13, 2015 Figure 31: CIMB REIT/BT Overview SREIT Hospitality Ascott Residence Trust Ascendas Hospitality Trust CDL Hospitality Trust Far East Hospitality Trust Frasers Hospitality Trust OUE Hospitality Trust Industrial AIMS AMP Ascendas REIT Cache Logistics Trust Cambridge Industrial Trust Keppel DC REIT Mapletree Industrial Trust Mapletree Logistics Trust Sabana Shariah Soilbuild Business Space REIT Viva Industrial Trust Office Capitacommercial Trust Frasers Commercial Trust Keppel REIT OUE Commercial REIT Retail CapitaMall Trust Frasers Centrepoint Trust Mapletree Commercial Trust SPH REIT Starhill Global REIT Suntec REIT Retail Ex-Sin CapitaRetail China Trust Croesus Retail Trust Lippo Malls Indonesia Retail Trust Mapletree Greater China Healthcare First REIT Parkway Life REIT Religare Health Trust Bloomberg Ticker Price as at Mkt Cap 13 Mar 15 (US $m) Last reported asset leverage Last stated NAV Price / Stated NAV Target Price (DDMbased) Rec. 2015 Yield 2016 Yield ART SP ASCHT SP CDREIT SP FEHT SP FHT SP OUEHT SP Simple Average $1.27 $0.69 $1.72 $0.82 $0.90 $0.93 $1,418 $554 $1,223 $1,052 $770 $894 38.5% 38.3% 31.7% 31.4% 40.0% 32.7% 35.4% 1.37 0.73 1.65 0.98 0.86 0.90 0.93 0.95 1.04 0.83 1.04 1.03 0.97 $1.30 NA $1.89 $0.77 NA $1.01 H NR H H NR A 7.0% 8.5% 6.9% 6.4% na 7.6% 7.3% 6.9% 8.7% 7.2% 6.6% na 8.1% 7.5% AAREIT SP AREIT SP CACHE SP CREIT SP KDCREIT SP MINT SP MLT SP SSREIT SP SBREIT SP VIT SP Simple Average $1.46 $2.47 $1.16 $0.70 $1.04 $1.53 $1.22 $0.91 $0.81 $0.81 $658 $4,315 $656 $645 $659 $1,934 $2,192 $475 $474 $366 31.7% 33.6% 34.9% 34.8% 27.8% 32.8% 34.7% 38.0% 35.4% 44.3% 34.8% 1.53 2.03 0.98 0.68 0.87 1.21 0.98 1.04 0.80 0.76 0.95 1.22 1.18 1.02 1.19 1.26 1.24 0.87 1.01 1.07 1.09 NA $2.41 $1.34 $0.69 NA $1.66 $1.30 NA NA $0.87 NR H A H NR A H NR NR A 7.8% 6.1% 7.7% 7.2% na 6.8% 6.7% 8.6% 7.2% 8.6% 7.4% 7.9% 6.4% 8.4% 7.3% 6.7% 7.1% 6.9% na 7.4% 8.8% 7.4% CCT SP FCOT SP KREIT SP OUECT SP Simple Average $1.70 $1.46 $1.22 $0.80 $3,637 $722 $2,814 $504 29.3% 37.2% 43.3% 38.3% 37.0% 1.71 1.59 1.41 1.10 0.99 0.92 0.87 0.72 0.88 $1.69 $1.54 $1.22 $0.93 RD H H A 5.2% 6.5% 5.7% 6.7% 6.0% 5.4% 6.5% 5.7% 6.6% 6.1% CT SP FCT SP MCT SP SPHREIT SP SGREIT SP SUN SP Simple Average $2.07 $2.01 $1.53 $1.04 $0.83 $1.86 $5,205 $1,337 $2,346 $1,895 $1,290 $3,385 33.8% 29.3% 37.9% 26.0% 28.6% 34.7% 31.7% 1.79 1.77 1.17 0.93 0.94 2.09 1.16 1.14 1.31 1.11 0.88 0.89 1.08 $2.18 $2.20 $1.54 $1.03 $0.88 $1.93 H A H H A H 5.4% 5.9% 5.2% 5.3% 6.3% 5.5% 5.6% 5.5% 6.1% 5.3% 5.5% 6.4% 5.8% 5.8% CRCT SP CRT SP LMRT SP MAGIC SP Simple Average $1.63 $0.94 $0.35 $1.04 $974 $350 $677 $2,032 28.7% 41.8% 26.7% 37.9% 33.8% 1.58 0.92 0.45 1.06 1.03 1.03 0.77 0.98 0.95 NA $1.10 $0.40 NA NR A A NR 6.7% 7.9% 9.3% 6.4% 7.6% 6.9% 8.0% 9.4% 6.6% 7.7% FIRT SP PREIT SP RHT SP Simple Average Simple average for SIN $1.35 $2.34 $1.06 $726 $1,028 $609 33.1% 35.2% 15.2% 27.8% 33.9% 1.02 1.68 0.87 1.33 1.39 1.22 1.31 1.06 $1.48 $2.60 $1.06 A A H 6.5% 5.9% 7.5% 6.6% 6.7% 6.6% 5.4% 8.2% 6.7% 6.8% SOURCES: CIMB, COMPANY REPORTS, BLOOMBERG MREIT Figure 32: Healthcare REITs Overview Retail Capitamalls Malaysia Trust IGB REIT Healthcare Sunway REITREITs Pavilion REIT First REIT Parkway IndustrialLife REIT Sabra Health Care REIT Inc Axis REIT LTC Properties Inc National Health Investors Inc Medical Properties Trust Inc Healthcare Realty Trust Inc Healthcare Trust of America In Generation Healthcare REIT Bbg Code Price as at Mkt Cap 13 Mar 15 (US $m) Last reported asset leverage CMMT MK $1.49 $719 27.2% as IGBREIT MKPrice (LC) $1.32 $1,236 26.0% at Mkt Cap (LC Target Price SREIT MK $1.51 $1,235 18.7% Bbg Code 15 $m) (DDM-based) PREIT MK 12 Mar$1.57 $1,250 33.4% FIRT SP $1.35 $726 $1.48 Simple Average 26.3% PREIT SP $2.34 $1,028 $2.60 SBRA US $31.48 $1,865 NA AXRB MK $3.60 $535 34.5% LTC US $1,544 NA Simple Average $43.43 34.5% NHI US $68.52 $2,574 NA Simple average for MAL 28.0% MPW US $14.36 $2,997 NA Simple average for ALL 33.0% HR US $26.73 $2,657 NA HTA US $26.97 $3,376 NA GHC AU $1.57 $214 NA Simple Average Last stated NAV 1.15 1.00 0.95 Rec. 1.10 A A NR 2.17 NR NR NR NR NR NR Price / Stated NAV Target Price (DDMbased) Rec. 1.30 $1.62 NR 1.32 $1.35 NR 2015 P/BV 1.59 $1.50 NR 1.43 (x) $1.532015 Yield NR 6.5% 1.41 1.35 1.38 5.9% 1.83 na 1.66 $3.85 NR na 1.66 na 2.28 na 1.46 1.30 na 1.12 2.28 na 2.34 na 1.36 na 1.76 na 2015 Yield 2016 Yield 6.5% 7.0% 5.7% 5.8% 5.4% 5.5% 2016 6.0% Yield6.5% 6.6% 6.2% 5.9% 5.4% 5.2% 5.7% 5.9% 5.2% 5.9% 5.7% 5.1% 5.9% 6.1% 6.7% 6.6% 6.7% 4.7% 4.6% 5.8% 5.5% SOURCES: CIMB, COMPANY REPORTS, BLOOMBERG 18 First REIT│Singapore March 13, 2015 6. RISKS Concentration risks FIRT is heavily reliant on its Indonesian healthcare properties and on rental payments from the master lessee as FIRT does not directly operate the properties. As such, any circumstance that adversely affects the operations of Indonesian hospitals or the master lessee’s ability to make rental payments will impact FIRT’s distributions. Land title risk In Indonesia, a Hak Guna Bangunan (HGB) title is the closest thing the country has to the internationally-recognised concept of ‘leasehold’ title. A holder of the HGB title has the right to erect, occupy and use buildings on a parcel of land and to sell all or part of such parcel. So far, the HGB titles have been extended upon expiry for several hospitals in 2012-2013. There is no assurance that there will be approvals for such renewals or extensions in the future, which could adversely affect the operations and FIRT’s ownership of the properties. Acquisition quality FIRT is likely to acquire healthcare assets around Asia that are deemed to be income-producing for its portfolio in order to grow inorganically. However, sometimes the added income produced by the property might not be able to fully compensate for the additional shares issued in order to fund the acquisition, thus leading to a lower DPU in the short run. However, FIRT’s strong management and close links to the Lippo Group in Indonesia should ensure that it has a stream of value-adding properties in the pipeline, which minimises the risk of a lower DPU due to acquisitions. Management fees payable in units FIRT has been paying out ~74% of its management fees in units for the past two years and we assume it will retain this rate. If the management switches to 100% or 50% of fees payable in cash from 2015 onwards, the impact to FIRT’s target price and FY15 and FY16 DPUs will be limited to ±3%. Figure 33: Sensitivity of DPU and target price to % of fees payable in units % of fees payable in units 100% 90% 80% 74% 70% 60% 50% FY15 DPU 3.6% 2.2% 0.8% 0.0% -0.6% -1.9% -3.3% FY16 DPU 3.5% 2.2% 0.8% 0.0% -0.5% -1.9% -3.2% TP 3.2% 2.0% 0.7% 0.0% -0.5% -1.7% -3.0% SOURCES: CIMB, COMPANY REPORTS Gearing limit The Collective Investment Schemes (CIS) code by MAS allows FIRT to borrow up to 35% of its deposited property without a credit rating and up to 60% if a credit rating is obtained and disclosed. We believe that FIRT is likely to keep its gearing below 35% in the near term. 19 First REIT│Singapore March 13, 2015 7. SWOT ANALYSIS Figure 34: SWOT Analysis Strengths Opportunities Most of FIRT’s assets are strategically located in parts of Indonesia with large catchment of potential patients. Experienced management team Well-equipped faclities with state-of-the-art equipment Siloam Hospitals have strong reputation and operating expertise in Indonesia Multi-billion dollar investment plan by the Indonesian government started in 1 Jan 2014 which will give many people first-time access to healthcare services. Plenty of room to grow - hospital bed and doctor-topopulation ratio far below global average. Weaknesses Threats Heavy dependence on Indonesia's healthcare market and Sponsor. Improper execution of the government’s healthcare plan could lead to lower-than-expected revenue. Political upheavals, natural disasters, insurgency movements, riots and governmental policies. SOURCES: CIMB, COMPANY REPORTS 20 First REIT│Singapore March 13, 2015 8. APPENDICES Management team CEO and executive director: Dr Ronnie Tan Keh Poo Dr Ronnie has been a director and CEO of Bowsprit since May 2006. Currently, he holds the posts of non-executive director and audit committee member of Auric Pacific Group Ltd. Previously, he served as CEO and director of AsiaMedic Ltd and senior executive in Parkway Holdings Ltd from 1998 to September 2004. He was also an executive director of Auric Pacific Group Ltd, responsible for the areas of business development as well as property and strategic investments, from October 2004 to July 2009. He also has experience working as a medical practitioner in various healthcare facilities in Australia and Singapore. CFO: Mr Tan Kok Mian, Victor Mr Tan has been the CFO of Bowsprit since July 2008 and was previously senior finance manager, responsible for financial operations in Bowsprit. Prior to that, he was at Parkway Holdings Ltd from 1997 to 2008, where he rose through the ranks as an accountant to become financial controller. Mr Tan also holds a professional qualification from the Association of Chartered Certified Accountants (ACCA). Senior asset and investment manager: Mr Chan Seng Leong, Jacky Mr Chan has over 20 years of experience in the property sector and is a member of the Singapore Institute of Surveyors and Valuers as well as a licensed appraiser (lands and buildings). Prior to joining Bowsprit, he was with Ascendas-MGM Funds Management Ltd and was the investment manager for Ascendas Real Estate Investment Trust, where he spearheaded multimillion-dollar real estate acquisitions and performed many other roles related to property valuation and investment. Mr Tan has a Master of Science (real estate) degree from the National University of Singapore and a Master in Business Administration degree from the University of Australia, Graduate School of Management. 21 First REIT│Singapore March 13, 2015 #01 DISCLAIMER This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the “Restrictions on Distributions” set out below). Any failure to comply with these limitations may constitute a violation of law. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB. Unless otherwise specified, this report is based upon sources which CIMB considers to be reasonable. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of CIMB or its affiliates to any person to buy or sell any investments. CIMB, its affiliates and related companies, their directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CIMB, its affiliates and its related companies do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report. CIMB or its affiliates may enter into an agreement with the company(ies) covered in this report relating to the production of research reports. CIMB may disclose the contents of this report to the company(ies) covered by it and may have amended the contents of this report following such disclosure. The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report. CIMB prohibits the analyst(s) who prepared this research report from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company. Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations and the research personnel involved in the preparation of this report may also participate in the solicitation of the businesses as described above. In reviewing this research report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. Reports relating to a specific geographical area are produced by the corresponding CIMB entity as listed in the table below. The term “CIMB” shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, CIMB Group Holdings Berhad ("CIMBGH") and its affiliates, subsidiaries and related companies. Country Australia Hong Kong Indonesia India Malaysia Singapore South Korea Taiwan Thailand CIMB Entity CIMB Securities (Australia) Limited CIMB Securities Limited PT CIMB Securities Indonesia CIMB Securities (India) Private Limited CIMB Investment Bank Berhad CIMB Research Pte. Ltd. CIMB Securities Limited, Korea Branch CIMB Securities Limited, Taiwan Branch CIMB Securities (Thailand) Co. Ltd. Regulated by Australian Securities & Investments Commission Securities and Futures Commission Hong Kong Financial Services Authority of Indonesia Securities and Exchange Board of India (SEBI) Securities Commission Malaysia Monetary Authority of Singapore Financial Services Commission and Financial Supervisory Service Financial Supervisory Commission Securities and Exchange Commission Thailand (i) As of March 12, 2015 CIMB has a proprietary position in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report: (a) AIMS AMP Capital Industrial REIT, Ascendas REIT, Cache Logistics Trust, Cambridge Industrial Trust, CapitaMall Trust, CDL Hospitality Trust, Croesus Retail Trust, Far East Hospitality Trust, First REIT, Frasers Centrepoint Trust, Frasers Commercial Trust, Keppel REIT, Mapletree Commercial Trust, Mapletree Greater China Commercial Trust, Mapletree Industrial Trust, Mapletree Logistics Trust, OUE Commercial REIT, OUE Hospitality Trust, Parkway Life REIT, Religare Health Trust, Starhill Global REIT, Suntec REIT (ii) As of March 13, 2015, the analyst(s) who prepared this report, and the associate(s), has / have an interest in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or 22 First REIT│Singapore March 13, 2015 recommended in this report: (a) The information contained in this research report is prepared from data believed to be correct and reliable at the time of issue of this report. CIMB may or may not issue regular reports on the subject matter of this report at any frequency and may cease to do so or change the periodicity of reports at any time. CIMB is under no obligation to update this report in the event of a material change to the information contained in this report. This report does not purport to contain all the information that a prospective investor may require. CIMB or any of its affiliates does not make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CIMB nor any of its affiliates nor its related persons shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CIMB and its affiliates’ clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments thereof. Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this research report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors. Australia: Despite anything in this report to the contrary, this research is provided in Australia by CIMB Securities (Australia) Limited (“CSAL”) (ABN 84 002 768 701, AFS Licence number 240 530). CSAL is a Market Participant of ASX Ltd, a Clearing Participant of ASX Clear Pty Ltd, a Settlement Participant of ASX Settlement Pty Ltd, and, a participant of Chi X Australia Pty Ltd. This research is only available in Australia to persons who are “wholesale clients” (within the meaning of the Corporations Act 2001 (Cth)) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. This research has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. France: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument. Hong Kong: This report is issued and distributed in Hong Kong by CIMB Securities Limited (“CHK”) which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CIMB Securities Limited. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only to clients of CHK. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CHK. Unless permitted to do so by the securities laws of Hong Kong, no person may issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the securities covered in this report, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong). CIMB Securities Limited does not make a market on the securities mentioned in the report. India: This report is issued and distributed in India by CIMB Securities (India) Private Limited (“CIMB India”) which is registered with SEBI as a stock-broker under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992 and in accordance with the provisions of Regulation 4 (g) of the Securities and Exchange Board of India (Investment Advisers) Regulations, 2013, CIMB India is not required to seek registration with SEBI as an Investment Adviser. The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of CIMB India and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by CIMB India or its affiliates. Indonesia: This report is issued and distributed by PT CIMB Securities Indonesia (“CIMBI”). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBI has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only to clients of CIMBI. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBI. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesia residents except in compliance with applicable Indonesian capital market laws and regulations. Malaysia: This report is issued and distributed by CIMB Investment Bank Berhad (“CIMB”). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMB has no obligation to update 23 First REIT│Singapore March 13, 2015 its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only to clients of CIMB. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB. New Zealand: In New Zealand, this report is for distribution only to persons whose principal business is the investment of money or who, in the course of, and for the purposes of their business, habitually invest money pursuant to Section 3(2)(a)(ii) of the Securities Act 1978. Singapore: This report is issued and distributed by CIMB Research Pte Ltd (“CIMBR”). Recipients of this report are to contact CIMBR in Singapore in respect of any matters arising from, or in connection with, this report. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBR has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only. If the recipient of this research report is not an accredited investor, expert investor or institutional investor, CIMBR accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBR. As of March 12, 2015, CIMBR does not have a proprietary position in the recommended securities in this report. CIMB Securities Singapore Pte Ltd and/or CIMB Bank Berhad have/has had an investment banking relationship with AIMS AMP Capital Industrial REIT within the preceding 12 months. CIMB Securities Singapore Pte Ltd and/or CIMB Bank does not make a market on the securities mentioned in the report. South Korea: This report is issued and distributed in South Korea by CIMB Securities Limited, Korea Branch ("CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. The views and opinions in this research report are our own as of the date hereof and are subject to change, and this report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial investment instruments and it is not intended as a solicitation for the purchase of any financial investment instrument. This publication is strictly confidential and is for private circulation only, and no part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB Korea. Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden. Taiwan: This research report is not an offer or marketing of foreign securities in Taiwan. The securities as referred to in this research report have not been and will not be registered with the Financial Supervisory Commission of the Republic of China pursuant to relevant securities laws and regulations and may not be offered or sold within the Republic of China through a public offering or in circumstances which constitutes an offer or a placement within the meaning of the Securities and Exchange Law of the Republic of China that requires a registration or approval of the Financial Supervisory Commission of the Republic of China. Thailand: This report is issued and distributed by CIMB Securities (Thailand) Company Limited (CIMBS). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBS has no obligation to update its opinion or the information in this research report. This publication is strictly confidential and is for private circulation only to clients of CIMBS. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBS. CIMB Securities (Thailand) Co., Ltd. may act or acts as Market Maker and issuer including offering of Derivative Warrants Underlying securities of the following securities. Investors should carefully read and study the details of the derivative warrants in the prospectus before making investment decisions. AAV, ADVANC, AMATA, ANAN, AOT, AP, ASP, BANPU, BAY, BBL, BCH, BCP, BEC, BECL, BGH, BH, BIGC, BJC, BJCHI, BLA, BLAND, BMCL, BTS, CENTEL, CK, CPALL, CPF, CPN, DCC, DELTA, DEMCO, DTAC, EARTH, EGCO, ERW, ESSO, GFPT, GLOBAL, GLOW, GUNKUL, HEMRAJ, HMPRO, INTUCH, IRPC, ITD, IVL, JAS, KBANK, KCE, KKP, KTB, KTC, LH, LOXLEY, LPN, M, MAJOR, MC, MCOT, MEGA, MINT, NOK, NYT, PS, PSL, PTT, PTTEP, PTTGC, QH, RATCH, ROBINS, RS, SAMART, SCB, SCC, SCCC, SIRI, SPALI, SPCG, SRICHA, STA, STEC, STPI, SVI, TASCO, TCAP, TFD, THAI, THCOM, THRE, THREL, TICON, TISCO, TMB, TOP, TPIPL, TTA, TTCL, TTW, TUF, UMI, UV, VGI, TRUE, WHA. Corporate Governance Report: The disclosure of the survey result of the Thai Institute of Directors Association (“IOD”) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may 24 First REIT│Singapore March 13, 2015 be changed after that date. CIMBS does not confirm nor certify the accuracy of such survey result. Score Range: Description: 90 - 100 Excellent 80 - 89 Very Good 70 - 79 Good Below 70 or N/A No Survey Result United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates. United Kingdom and Europe: In the United Kingdom and European Economic Area, this report is being disseminated by CIMB Securities (UK) Limited (“CIMB UK”). CIMB UK is authorised and regulated by the Financial Conduct Authority and its registered office is at 27 Knightsbridge, London, SW1X 7YB. This report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are persons that are eligible counterparties and professional clients of CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”); (c) are persons falling within Article 49 (2) (a) to (d) (“high net worth companies, unincorporated associations etc”) of the Order; (d) are outside the United Kingdom; or (e) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with any investments to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons. Only where this report is labelled as non-independent, it does not provide an impartial or objective assessment of the subject matter and does not constitute independent "investment research" under the applicable rules of the Financial Conduct Authority in the UK. Consequently, any such non-independent report will not have been prepared in accordance with legal requirements designed to promote the independence of investment research and will not subject to any prohibition on dealing ahead of the dissemination of investment research. United States: This research report is distributed in the United States of America by CIMB Securities (USA) Inc, a U.S.-registered broker-dealer and a related company of CIMB Research Pte Ltd, CIMB Investment Bank Berhad, PT CIMB Securities Indonesia, CIMB Securities (Thailand) Co. Ltd, CIMB Securities Limited, CIMB Securities (Australia) Limited, CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CIMB Securities (USA) Inc. CIMB Securities (USA) Inc does not make a market on the securities mentioned in the report. Other jurisdictions: In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Distribution of stock ratings and investment banking clients for quarter ended on 31 December 2014 1586 companies under coverage for quarter ended on 31 December 2014 Rating Distribution (%) Investment Banking clients (%) Add 58.4% 6.0% Hold 29.4% 4.3% Reduce 12.2% 1.0% Spitzer Chart for stock being researched ( 2 year data ) 25 First REIT│Singapore March 13, 2015 First REIT (FIRT SP) Price Close 1.500 1.400 1.300 1.200 1.100 1.000 0.900 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Corporate Governance Report of Thai Listed Companies (CGR). CG Rating by the Thai Institute of Directors Association (Thai IOD) in 2014. AAV – Very Good, ADVANC – Very Good, AEONTS – not available, AMATA - Good, ANAN – Very Good, AOT – Very Good, AP - Good, ASK – Very Good, ASP – Very Good, BANPU – Very Good , BAY – Very Good , BBL – Very Good, BCH – not available, BCP - Excellent, BEAUTY – Good, BEC - Good, BECL – Very Good, BGH - not available, BH - Good, BIGC - Very Good, BJC – Good, BLA – Very Good, BMCL - Very Good, BTS - Excellent, CCET – Good, CENTEL – Very Good, CHG – not available, CK – Very Good, CPALL – not available, CPF – Very Good, CPN - Excellent, DELTA - Very Good, DEMCO – Good, DTAC – Very Good, EA - Good, ECL – not available, EGCO - Excellent, GFPT - Very Good, GLOBAL - Good, GLOW - Good, GRAMMY - Excellent, HANA Excellent, HEMRAJ – Very Good, HMPRO - Very Good, ICHI - not available, INTUCH - Excellent, ITD – Good, IVL - Excellent, JAS – not available, JUBILE – not available, KAMART – not available, KBANK - Excellent, KCE - Very Good, KGI – Good, KKP – Excellent, KTB - Excellent, KTC – Good, LH - Very Good, LPN – Very Good, M - not available, MAJOR - Good, MAKRO – Good, MBKET – Good, MC – Very Good, MCOT – Very Good, MEGA – Good, MINT Excellent, OFM – Very Good, OISHI – Good, PS – Very Good, PSL - Excellent, PTT - Excellent, PTTEP - Excellent, PTTGC - Excellent, QH – Very Good, RATCH – Very Good, ROBINS – Very Good, RS – Very Good, SAMART - Excellent, SAPPE - not available, SAT – Excellent, SAWAD – not available, SC – Excellent, SCB - Excellent, SCBLIF – Good, SCC – Very Good, SCCC - Good, SIM - Excellent, SIRI - Good, SPALI - Excellent, STA – Very Good, STEC - Good, SVI – Very Good, TASCO – Good, TCAP – Very Good, THAI – Very Good, THANI – Very Good, THCOM – Very Good, THRE – not available, THREL – Good, TICON – Good, TISCO - Excellent, TK – Very Good, TMB - Excellent, TOP - Excellent, TRUE – Very Good, TTW – Very Good, TUF - Good, VGI – Very Good, WORK – not available. CIMB Recommendation Framework Stock Ratings Definition: Add The stock’s total return is expected to exceed 10% over the next 12 months. Hold The stock’s total return is expected to be between 0% and positive 10% over the next 12 months. Reduce The stock’s total return is expected to fall below 0% or more over the next 12 months. The total expected return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net dividend yields of the stock. Stock price targets have an investment horizon of 12 months. Sector Ratings Overweight Neutral Underweight Definition: An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation. A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation. An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation. Country Ratings Overweight Neutral Underweight Definition: An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark. A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark. An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark. *Prior to December 2013 CIMB recommendation framework for stocks listed on the Singapore Stock Exchange, Bursa Malaysia, Stock Exchange of Thailand, Jakarta Stock Exchange, Australian Securities Exchange, Taiwan Stock Exchange and National Stock Exchange of India/Bombay Stock Exchange were based on a stock’s total return relative to the relevant benchmarks total return. Outperform: expected to exceed by 5% or more over the next 12 months. Neutral: expected to be within +/-5% over the next 12 months. Underperform: expected to be below by 5% or more over the next 12 months. Trading Buy: expected to exceed by 3% or more over the next 3 months. Trading Sell: expected to be below by 3% or more over the next 3 months. For stocks listed on Korea Exchange, Hong Kong Stock Exchange and China listings on the Singapore Stock Exchange. Outperform: Expected positive total returns of 10% or more over the next 12 months. Neutral: Expected total returns of between -10% and +10% over the next 12 months. Underperform: Expected negative total returns of 10% or more over the next 12 months. Trading Buy: Expected positive total returns of 10% or more over the next 3 months. Trading Sell: Expected negative total returns of 10% or more over the next 3 months. 26
© Copyright 2024